Merck Collaborates with Seven and Eight BioPharmaceuticals to Evaluate the BDB001 + Keytruda (pembrolizumab) for Advanced Solid Tumors

 Merck Collaborates with Seven and Eight BioPharmaceuticals to Evaluate the BDB001 + Keytruda (pembrolizumab) for Advanced Solid Tumors

Merck’s Keytruda (pembrolizumab) Receives FDA’s Approval for 1L Treatment of Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma

Shots:

  • The companies collaborate to explore the combination of Seven and Eight’s BDB001 and Merck’s Keytruda (pembrolizumab) for treating patients with advanced solid tumors
  • As per the agreement, Seven and Eight BioPharmaceuticals will conduct the clinical study assessing the combination regimen to address the unmet medical needs of patients with advanced and difficult-to-treat tumor types
  • BDB001 is an immune modulator targeting TLR 7 & 8 while Keytruda is an anti-PD-1 therapy, act by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2 thus activating T lymphocytes affecting both tumor and healthy cells

Click here to­ read full press release/ article | Ref: Businesswire | Image: Bloomberg

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post